Tag: operations

Folsom, NJ, June 01, 2026 (GLOBE NEWSWIRE) -- Media Contact: SJI Media Relations
609-561-9000 ext. 4131
media@sjindustries.com

LITTLE ROCK, Ark., June 01, 2026 (GLOBE NEWSWIRE) -- Uniti Group Inc. (the “Company,” “Uniti,” or “we”) (Nasdaq: UNIT) today announced that Kinetic ABS Issuer LLC, a limited-purpose, bankruptcy remote subsidiary of Uniti (the “Issuer”), has commenced an offering of $1,140,710,000 aggregate principal amount of secured fiber network revenue term notes (the “Notes”), the issuance and sale of which are subject to market conditions and other factors. The Notes are expected to have an anticipated repayment date in June 2033. The Notes are expected to be secured by certain residential fiber network assets and related customer agreements in the States of Texas, Arkansas, Kentucky, Ohio, Georgia, Iowa, Alabama, Florida, North Carolina and Oklahoma. Each of the Issuer and its direct parent entity and subsidiaries are designated as “unrestricted subsidiaries” under Uniti’s credit agreement and the indentures governing its outstanding senior notes.

Line-fit integration of the Viasat Hybrid SATCOM Approach for the C-130J presents opportunity to expand high-capacity, resilient connectivity across multi-mission airlift operations

PHOENIX, May 29, 2026 (GLOBE NEWSWIRE) -- Global Water Resources, Inc. (NASDAQ: GWRS), a pure-play water resource management company, has declared under its dividend policy a monthly cash dividend in the amount of $0.02533 per common share (an annual dividend rate of $0.30396 per share).

Seasoned international finance leader to support Kyivstar’s continued growth and digital transformation

Announces Progress in Second U.S. Department of War Program of Record Through Tier-1 Defense Partner Supporting the U.S. Army’s LASSO Program

ROCKVILLE, Md. and SUZHOU, China, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it has received clearance by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to conduct GLORA-4 study (NCT06641414), a global registrational Phase III study of lisaftoclax (APG-2575), a proprietary Bcl-2 inhibitor, in combination with azacitidine (AZA), for the treatment of patients with newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS).

NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of CTO Realty Growth, Inc. (NYSE: CTO, CTO-PA) between February 18, 2021 and June 24, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 7, 2025.